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Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, and can
be subcategorized histologically and/or based on PAX-FOXO1 fusion gene status. Over
the last four decades, there have been no significant improvements in clinical outcomes
for advanced and metastatic RMS patients, underscoring a need for new treatment
options for these groups. Despite significant advancements in our understanding of the
genomic landscape and underlying biological mechanisms governing RMS that have
informed the identification of novel therapeutic targets, development of these therapies
in clinical trials has lagged far behind. In this review, we summarize the current frontline
multi-modality therapy for RMS according to pediatric protocols, highlight emerging
targeted therapies and immunotherapies identified by preclinical studies, and discuss
early clinical trial data and the implications they hold for future clinical development.
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INTRODUCTION
Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, comprising 4.5%
of all childhood cancer with an annual incidence of 4.5 cases per 1 million children (1, 2). RMS
cells resemble skeletal muscle progenitor cells, though they can arise from non-skeletal tissue
origins (3). RMS is historically classified based on histopathologic features into distinct clinical
subtypes— embryonal RMS (ERMS), alveolar RMS (ARMS), pleomorphic, and spindle cell and
sclerosing RMS (ssRMS) (4, 5). ERMS represents the majority of cases and is associated with a
favorable prognosis, while ARMS ismore clinically aggressive due to a propensity formetastasis and
recurrence (6–8). Eighty percentage of ERMS tumors are characterized by a loss of heterozygosity
at the 11p15 locus, and they generally represent a more biologically heterogeneous group of tumors
compared to ARMS (1). The recently recognized subtype, spindle cell and sclerosing RMS is a
rare variant of RMS characterized by recurring fusions of VGLL2 or NOCA2 and has a favorable
prognosis, so it is treated without the aggressive multimodal regimens used to treat ARMS and
ERMS (5). In this review, we focus on the ARMS and ERMS subtypes.
The majority of ARMS tumors harbor a recurrent chromosomal translocation, t(2;13)(q35;q14)
or t(1;13)(p36;q14). The 2;13 and 1;14 translocations encode for a chimeric transcription
factor (TF), consisting of the N-terminal DNA binding domain of PAX3 or PAX7 fused to
the C-terminal transactivation domain of FOXO1 (9, 10). Of all ARMS patients, approximately
60% express PAX3-FOXO1, 20% express PAX7-FOXO1, 20% are fusion negative (11, 12), and
a small subset express rare variants such as PAX3-FOXO4 or PAX3-NOXA1 (12). Patients with
the PAX7-FOXO1 rearrangement have superior overall survival (82%) compared to patients
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with the PAX3-FOXO1 rearrangement (61%) (12). Notably,
chromosomal amplificationwas reported in themajority (93%) of
PAX7-FOXO1 cases compared to PAX3-FOXO1 (9%) (13), raising
the question of whether fusion gene amplification is linked to
more favorable outcomes. At this point in time, it is unknown
whether the PAX7 fusion partner or gene amplification is the
main determinant of favorable outcome, but prospective tracking
of fusion gene amplification in COG study ARST1431 is expected
to clarify if gene amplifications contribute toward the observed
difference. The remaining 20% of fusion-negative ARMS tumors
present a similar molecular profile and clinical outcome to
the ERMS subtype (14–16). The PAX-FOXO1 chimeric protein
behaves as a highly active transcription factor to drive aberrant
gene expression, encoding for downstream gene targets required
for oncogenic transformation. The oncogenic capacity of the
PAX-FOXO1 fusion proteins has been well characterized by
multiple studies and has been shown to act as a dominant-acting
oncogene in driving tumorigenesis in fusion-positive RMS (FP
RMS) (4, 17). On the other hand, fusion-negative RMS (FN
RMS) is characterized by higher rates of aneuploidy and single-
nucleotide variations, with the RAS pathway most commonly
activated in the majority of FN tumors (18–20). There is a
known link between RMS and cancer predisposition syndromes,
such as Li-Frameni syndrome, neurofibromatosis, Beckwith-
Wiedemann syndrome, and Costello syndrome (19).
Over 90% of patients with low-risk localized disease can be
cured with multi-modal therapy, but overall survival rates of
patients with metastatic or recurrent disease remain dismal at
21% and 30%, respectively (21, 22). Because RMS is a rare
disease, cooperative trials in Europe (European pediatric Soft
Tissue Sarcoma Study Group (23), Cooperative Weichteilsarkom
Studiengruppe der Gesellschaft für pädiatrische Onkologie und
Hämatologie (CWS) (21, 23) and North America (Children’s
Oncology Group) (24) have been crucial for clinical study of this
disease. Given that no significant improvements in the survival
outcomes of metastatic and recurrent RMS patients in the last
30 years have been reached, there is an unmet need for novel
treatment paradigms. Moreover, RMS patients could benefit
from molecularly targeted and immunotherapeutic approaches,
which could reduce the treatment-associated toxicities caused
by current chemotherapy and radiation therapy (RT). Because
funding of drug development for a rare childhood cancer such as
RMS is limited, preclinical studies have focused on molecularly
actionable targets that have been studied in other human
cancers, many of which have clinically approved therapies.
Here, we review the current frontline therapies, followed by an
overview of emerging targeted therapies and immunotherapies in
RMS (Figure 1).
FRONTLINE THERAPY
The last five decades of cooperative group trials for RMS have
improved the 5-year overall survival of patients with pediatric
RMS, which now exceeds 70% (25–28). These improvements
follow collaborative group clinical trial efforts, which have
enabled improvements in chemotherapeutic dosing regimens,
local control, and management of treatment-related toxicities.
However, improvements in cure rate have generally been limited
to patients with low- and intermediate-risk RMS, while no
significant progress has been reached in cure rates for patients
with advanced or metastatic RMS. Both European and American
cooperative group studies have developed more sophisticated
risk stratification systems to include more comprehensive
prognostic features [patient age, tumor size and site, lymph node
involvement, and/ or metastases and surgical group classification
(IRS)] that allow more personalized and effective treatment
approaches (29, 30).
The support for inclusion of fusion status for risk stratification
in clinical trials has been disputed by conflicting studies. A
study by Missiaglia et al. reported that positive fusion status
correlated with an inferior clinical outcome, while Stegmaier et al.
reported there to be no correlation between fusion status and
clinical outcome (31, 32). The inconsistent results from these
retrospective studies can be partly explained by methodological
biases of convenience sampling, where samples are not truly
representative of the whole population but rather chosen based
on archival sample availability (33–35). Support for the inclusion
of fusion status in future clinical trials comes from retrospective
analyses such as one by Selfe et al., which argued that re-
assignment based on fusion status could spare a significant
number of patients from treatment-associated toxicities caused
by unnecessary intensive therapy (36). Prompted by conflicting
results from previous studies, in 2019 the COG re-examined the
prognostic importance of fusion status and determined it was
the second most important prognostic factor, after metastatic
status (37). Taken together with additional supporting evidence
for the inclusion of fusion status as a significant prognostic
marker (31, 38) and evidence that FN ARMS and ERMS are
molecularly indistinguishable (16), ARST1431 was the first COG
trial to use fusion status instead of histopathological status (39).
On the European side, fusion gene status will now be used instead
of histological status for risk stratification in EpSSG trials (40).
It should be mentioned that currently in Europe and North
America, high-risk stratification is assigned based on metastatic
status, irrespective of fusion status and histology. Whereas,
previous studies focused on fusion status as an important
prognostic marker in low- and intermediate-risk RMS (38, 41,
42), a review of high-risk RMS cases found that fusion status does
not offer the same level of predictive value for metastatic patients.
In cases of metastatic RMS, clinical risk factors remain the major
predictors of outcome.
The current frontline treatment for all risk-groups of
RMS is a multi-modal approach, comprising chemotherapy,
surgical resection, and/or radiation therapy. In North America,
the standard chemotherapy backbone includes vincristine,
actinomycin D, and cyclophosphamide (VAC) (43, 44) and in
Europe, the backbone consists of isofasfamide, vincristine, and
actinomycin D (IVA) (45). A randomized trial confirmed there
to be no significant difference in patient outcomes between the
two treatment combinations, so VAC and IVA have continued
to be used in their respective regions (25). Since the VAC/IVA
regimen was first established four decades ago, the chemotherapy
backbone has remained the same besides changes in duration,
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FIGURE 1 | Pipeline of preclinical and clinical development for targeted therapies and immunotherapies of rhabdomyosarcoma.
dosage, and route of administration. After three decades of
controversy regarding the inclusion of doxorubicin in the
chemotherapy regimen (43, 46–48), an open-label phase 3
trial (EpSSG RMS 2005) conclusively showed that addition of
doxorubicin to the standard IVA backbone did not improve
patient outcomes in high-risk rhabdomyosarcoma (49). Because
of doxorubicin’s known risk of cardiotoxicity (especially in
younger patients), there is a lack of justification for its continued
inclusion in the chemotherapy regimen.
Localized RMS
Today, children with low-risk RMS (localized to favorable
anatomical sites, grossly resected ERMS) treated with frontline
multi-modality therapy have excellent outcomes (90% relapse-
free survival). Recent clinical research on low-risk RMS has
focused on reducing toxicity of treatment by decreasing dosage
and duration of alkylating agent, without compromising the
ability to prevent disease recurrence. The alkylating agent,
cyclophosphamide used in the VAC chemotherapy regimen
is known to cause acute and late effects, including severe
myelosuppression, infectious complications, and infertility (50).
Aiming to minimize treatment-related toxicities, the COG
ARST0331 study showed that shorter duration therapy (which
included lower-dose cyclophosphamide) and radiation therapy
(RT) did not compromise failure-free survival for the majority
of patients (51).
Eradication of gross primary tumor is achieved by a
combination of surgery and/or RT, in addition to the standard
systemic chemotherapy backbone. RT is included in the
frontline treatment for nearly all RMS patients, although long-
term toxicity poses a significant concern in younger patients
(52). Strategies to reduce radiation-related toxicities include
incorporation of intensity-modulated RT (IMRT) or proton
bean RT and the use of brachytherapy for specific sites e.g.,
bladder or vagina, both of which are assumed to reduce late
toxicities (skeletal muscle/soft tissue changes, joint stiffness,
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skeletal growth problems, and secondary malignancy) (53–56). It
is worth noting a difference in treatment philosophies between
North American and European studies. European studies use
overall survival as the study end-point, preferring less aggressive
local treatment (omission of RT if possible) to mitigate late
toxicities, while tolerating a greater risk of relapsed disease.
Conversely, North American studies tend to focus on event-free
survival as the study end-point, so treatment strategies favor
more aggressive local treatment with radiation therapy (1).
In localized high-risk RMS, the benefit of additional
maintenance therapy is currently investigated by the two
European groups EpSSG and CWS in two international
trials. The EpSSG reported an improved overall survival
with cyclophosphamide/vinorelbine in the first preliminary
assessment at the end of the recruitment period of EpSSG
RMS2005 (2008–2013) (57). The ongoing CWS-2007HR trial is a
randomized study of whether the addition of an oral maintenance
regimen of O-TIE (etoposide, idarubicin, tofosfamide) can
benefit patients with localized high-risk RMS. The EpSSG RMS
2005 randomized phase III trial reported that addition of
maintenance chemotherapy improved survival for patients with
non-metastatic high-risk RMS (58, 59). Since this study was
published in 2019, vinorelbine/cyclophosphamide maintenance
chemotherapy has been established as the new standard-of-care
for treatment of localized high-risk RMS.
Metastatic RMS
Survival outcomes for patients with metastatic disease remain
dismal (event free survival <20%, excluding patients <10 years
old diagnosed with ERMS), and the frontline treatment has
not advanced significantly over the last 30 years (22, 29, 60).
Today in Europe and the United States, the Oberlin score
is used for risk stratification and classification of metastatic
RMS, assigning a risk score based on patient age, primary
tumor site, number of metastases, histology, and bone marrow
involvement (29). Unlike for localized disease, for metastatic
RMS multimodal therapy frequently fails due to lack of a proper
local therapy to treat metastatic sites such as the bone marrow
and lungs. A European trial for metastatic RMS reported that
high-dose chemotherapy (HD-CT) did not significantly improve
survival outcomes compared to standard chemotherapy, despite
increased treatment-associated toxicities (61). This report is
consistent with a retrospective analysis of 389 patients, which
found no significant improvements in survival after HD-CT with
hematopoietic stem cell rescue in the treatment of metastatic
rhabdomyosarcoma (62). Results from the COG ARST0431
trial for patients with high-risk RMS found that high-dose
chemotherapy (dose-compressed cycles of ifosfamide/etoposide
and vincristine/doxorubicin/cyclophosphamide, irinotecan, and
radiation) did not produce meaningful benefit for most patients,
except for a minority of patients with embryonal histology and
limited metastatic disease (restricted to lungs) (63). Notably, the
inefficacy of HD-CT has also been documented in trials for other
metastatic childhood solid tumors, including Ewing sarcoma and
osteosarcoma (64–66). Observations from a trial conducted on
pediatric neuroblastoma patients treated with HD-CT and stem
cell transplantation rescue found there were long-term health
consequences (hearing loss, gonadal insufficiency) associated
with treatment (67). An important recent study by Merker
et al. reported that haploidentical allogeneic hematopoietic stem
cell transplantation (HSCT) has inferior outcomes compared to
standard maintenance therapies, such as O-TIE (68). Here, the
authors argue against the use of allogeneic HSCT, which hasmore
severe side effects than standard maintenance therapy. Taken
together, HD-CT and allogeneic HSCT should be discontinued
because they failed to achieve curative effects in metastatic
RMS, and similar outcomes can be achieved with the less toxic
maintenance therapies.
Ongoing European studies investigating the role of
maintenance therapy are based off a report by Klingebiel
et al. for the HD CWS-96 study. The HD CWS-96 trial was
a non-randomized trial comparing the efficacy of high dose
therapy (HDT) vs. oral maintenance therapy (OMT) in patients
with stage IV soft tissue sarcoma (69). While high dose therapy
failed to improve survival, oral maintenance therapy was a
promising alternative, since the oral administration can provide
long lasting exposure to chemotherapy without increasing toxic
side effects. As such, an OMT regimen of O-TIE is the current
standard of care within the CWS, while an OMT combination
of cyclophosphamide/vinorelbine is used within the EpSSG
for metastatic RMS. In North America, the COG does not
currently regard maintenance therapy as the standard of care for
metastatic RMS; however, COG study protocols include much
longer absolute durations of therapy. There are considerations
as to whether the concept of maintenance therapy or absolute
duration of therapy is the more relevant metric for treatment.
In cases of metastatic disease with distant spread of disease
from the primary tumor site, the value of localized treatment of
the primary tumor is often overlooked. A European retrospective
study demonstrated that aggressive localized treatment of the
primary tumor (combined surgical resection and RT compared
to either alone) led to improved outcomes in patients with
metastatic RMS (70). Another retrospective study found that
local treatment to all metastatic sites in stage IV RMS was
associated with an improved progression-free survival (PFS) and
overall survival (OS) at 5 years (71). These lines of evidence
support the importance of strong localized therapy at both
primary and metastatic sites. However, extended local therapy
(RT or chemotherapy) is not always feasible in patients. Other
directions that are currently being considered include targeting
genetically quiescent cells with the administration of oral
maintenance therapy (69) and efforts to design therapeutic agents
specifically targeted toward the metastatic phenotype (72, 73).
Relapsed RMS
Approximately one-third of pediatric RMS patients will
experience progressive disease or relapse, with a median time
to relapse/progression of 13 months from initial diagnosis
(74). Based on multivariate statistical modeling, it is now
possible to predict the chance of salvage following first relapse
of localized RMS based on a number of factors associated
with worse outcome: metastatic status, prior exposure to
RT and chemotherapy, unfavorable size and site of the
tumor, lymph node involvement, alveolar histology, and
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shorter time to relapse (75). In general, most relapsed RMS
patients are treated with chemotherapy and local control
(surgery and/or RT). Knowing the chance of salvage on
a case-by-case basis is important for deciding treatment
options for each patient. For instance, patients with a
very low chance of cure will not respond effectively to
salvage therapy, so these patients should be prioritized for
enrollment in experimental trials (75). Meanwhile, patients
who demonstrate relapse after low-risk disease may benefit
from salvage chemotherapy, such as irinotecan/vincristine
or alternating vincristine/doxorubicin/cyclophosphamide, and
etoposide/ofosfamide (76, 77). Disappointingly, phase II trials for
children with relapsed RMS have not demonstrated meaningful,
single-agent activity of targeted inhibitors, such as a monoclonal
antibody against IGF-1R (R1507) and a multi-kinase inhibitor,
sorafenib (78, 79). Clearly, there is a need to understand why
these therapeutic agents which show promise in the pre-clinical
stage fail to translate into meaningful outcomes in patients, and
to identify strategies targeting resistance mechanisms hindering
their clinical efficacy. At any rate, novel therapeutic targets
(Table 1) that are backed by supportive clinical evidence should
also be explored as experimental options for patients with
relapsed RMS.
Given the inherent limitations of therapeutic options available
for metastatic and recurrent RMS, experimental trials should
prioritize patients with metastatic or recurrent disease, including
emerging targeted therapy and immunotherapy strategies. Below,
we summarize the key preclinical and clinical findings on novel
targeted therapy and immunotherapy options in RMS (Figure 2).
TARGETED THERAPY
PAX-FOXO1
Directly Targeting PAX-FOXO1 Fusion Protein
In FP RMS, the chimeric transcription factor, PAX-FOXO1
presents the most direct and promising target. Conceptually,
it is more effective to target one upstream transcription factor
than multiple downstream signaling cascades and hundreds of
target genes. Moreover, because PAX-FOXO1 fusion protein is
uniquely expressed in tumor cells but not in normal cells, it is
an attractive target. Small molecule inhibitors against oncogenic
fusion proteins have achieved remarkable clinical success in some
human cancers, such as the targeting of BCR-ABL in leukemia
and EML4-ALK1 in lung carcinoma (80, 81). Until recently, TFs
were considered to be an “undruggable” class of proteins due to
an absence of deep hydrophobic pockets, large protein-protein
interaction interfaces, and nuclear localization (82). Today, the
opinion on drugging transcription factors is beginning to shift
[reviewed by (83)], as approaches to inhibit transcription factors
have demonstrated some success in preclinical and clinical
studies. Novel approaches to drug transcription factors are
currently being investigated in other disease contexts, with the
possibility of adapting these strategies for targeting PAX-FOXO1.
One experimental approach is the use of nanoparticle carriers
to deliver naked siRNA or antisense oligonucleotides (ASO)
into tumor cells to silence specific genes. The advantage of this
approach is that any gene can theoretically be targeted by simply
knowing the complementary base pairing for the gene of interest.
A recent publication demonstrated that liposome-protamine-
siRNA (LRP) particles targeting PAX3-FOXO1 were efficiently
delivered to ARMS cell lines and downregulated PAX3-FOXO1
and its target genes in vitro, leading to delayed tumor growth
and inhibition of tumor initiation in ARMS xenograft models
(84). However, safety concerns over off-target effects by the RNAi
transcripts and the toxicity of delivery systems remain significant
obstacles to translation of this approach into the clinic.
To date, there have not been significant efforts to design
inhibitors which directly bind PAX-FOXO1. Yet, emerging
strategies to directly drug transcription factors are currently
being explored in other human cancers. These new approaches
include modulation of the auto-inhibitory state of transcription
factors, proteolysis targeting chimeras (PROTACs), use of
cysteine reactive inhibitors, and targeting intrinsically disordered
regions [reviewed in (83)]. Notably, PROTAC uses a bifunctional
molecule simultaneously targeting the protein of interest and
engaging an E3 ubiquitin ligase to promote proteasomal
degradation of the target. So far, it has not been explored in
RMS, but the documented efficacy in other studies support its
consideration for targeting PAX-FOXO1 (85–87). The advantage
of the PROTAC approach over traditional pharmacological
inhibition is that a single molecule could be used for multiple
rounds of proteasome-targeted degradation. The first step would
be to identify ligands capable of binding PAX-FOXO1 with
sufficient specificity and affinity. This is more feasible than other
inhibitory approaches, since the ligand only needs to bind to a
tractable surface, rather than a specific functional site which is
much harder to target.
Coregulators of PAX-FOXO1
An alternative approach to disrupting PAX-FOXO1 activity is
to target essential protein-protein interactions with co-regulators
and chromatin-remodeling proteins required for oncogenic
transcriptional activity. PAX-FOXO1 acts as a pioneering
TF to establish looped super-enhancers, recruiting chromatin
remodeling proteins, coactivators, and other TFs to aberrantly
drive transcription at target genes. Only a small subset of
TFs form the core regulatory circuit of TFs, which cancer
cells are uniquely dependent on (88, 89). In FP ARMS, PAX-
FOXO1 orchestrates the formation of super-enhancers, which
drive the transcription of core regulatory TFs in a strong
autoregulatory loop. A promising therapeutic approach is to
disassemble the super-enhancer with small molecule inhibitors,
thereby disrupting the oncogenic core regulatory circuit (90).
The selective disruption of super-enhancers by small molecule
inhibitors can specifically suppress transcription at key oncogenic
drivers (91). Gryder et al. was first to demonstrate a mechanistic
link between the chromatin reader, BET bromodomain-
containing protein (BRD4) and PAX3-FOXO1. The authors show
that BRD4 small molecule inhibitor, JQ1 selectively disrupts the
interaction between BRD4 and PAX3-FOXO1, leading to rapid
degradation of the fusion gene and abrogation of transcriptional
output (89). Another study reported that the antitumor activity
of JQ1 is mediated by a decrease in angiogenic activity (92),
which is consistent with the hypothesis that disruption of the
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BRD4 JQ1, OTX015 Preclinical NA
CHD4 ED2-AD101 (SMARCA5/CHD4 dual
inhibitor)
Preclinical NA




ALK Critotinib Clinical (II) 2011-001988-52
PLK1 Volasertib Preclinicial NA
GSK3β Tideglusib, LY2090314, 9-ING-41 Preclinical NA
PI3K/mTOR Omipalisib, Temsirolimus Clinical (I/II) 2007-000371-42 NCT00106353;
NCT01222715
MEK1 Cobimetinib Clinical (I/II) 2014-004685-25
FGFR Erdafitinib Clinical (II) NCT03210714;
NCT03155620
IGF-1R R1507 (mAb) Clinical (II) 2007-003940-30 NCT00642941
VEGF Bevacizumab (mAb) Clinical (II) 2013-003595-12 NCT01222715
Multi-RTKs Regorafenib Clinical (II) 2013-003579-36 NCT01900743
SMO LDE225, Erismodegib, Vismodegib,
Sonidegib
Clinical (II) 2010-019348-37 NCT01125800
NOTCH RO4929097, MK0572, brontictuzumab
(mAb), tarextumab (mAb)
Preclinical NA
CDK4/6 Palbociclib, Ribociclib, Abemaciclib Preclinical NA
Wee1 AZD1775 Clinical (I/II) NCT02095132
PARP Olaparib, Iniparib, Veliparib Clinical (II) NCT03155620;
NCT03233204
Bcl-2 Venetoclax, ABT-737 Preclinical NA
XIAP Smac mimetics (LCL161) Preclinical NA
Immunotherapy
B7-H3 Enoblituzumab (mAb) Clinical (I) NCT02982941
HER2 Autologous HER2-specific CAR T cells Clinical (I) NCT00902044
EGFR Autologogous EGFR-specific CAR T cells Clinical (I) NCT03618381
CTLA-4 Ipilimumab Clinical (I/II) NCT02304458;
NCT01445379
PD-1/PD-L1 Nivolumab, Pembrolizumab, Atezolizumab Clinical (I/II) 2014-004697-41;
2018-000127-14
NCT02304458
super-enhancer ablates transcriptional output of gene targets, one
of which is vascular endothelial growth factor (VEGF). Among
the five structurally diverse BET bromodomain inhibitors tested
in this study, OTX015 was reported to be most potent across
a range of FP RMS cell lines, but its clinical efficacy has not
been evaluated. A related therapeutic strategy targets chromatin
helix DNA binding protein 4 (CHD4), an ATP-dependent
chromatin remodeling protein which plays an integral role in the
Nucleosome Remodeling Deacetylase (NuRD) complex. CHD4
is required for the recruitment of the transcriptional machinery,
and its role in nucleosome eviction is required for transcription
to proceed. (93) Upon knockdown of CHD4 in vitro, gene
expression profiling showed that CHD4 activity is essential for
the expression of a subset of PAX3-FOXO1 target genes, and that
the observed effect was specific to FP RMS (93). Independently,
another group found that CHD4 acts as a crucial coregulator of
PAX3-FOXO1 (identified as a top candidate from a siRNA screen
of 60 candidate interactors), suggesting the role of CHD4 as a
therapeutic target in FP RMS (93). A first-in-class inhibitor (ED2-
AD101) of SMARCA5/CHD4was recently shown to suppress cell
growth in acute myeloid leukemia (AML) cells, but no inhibitors
specifically targeting CHD4 are currently available for clinical
use (94).
Other studies have implicated that inhibition of another
epigenetic regulator, histone deacetylase (HDAC) has antitumor
effects in preclinical RMS models. A recent study designed
a screen for epigenetic chemical probes to differentiate
between super-enhancer driven transcription and constitutive
transcription, revealing that the acetylation-axis is more
important for the core regulatory TF circuit than the
methylation-axis (90). Independent studies have reported
the ability of HDAC inhibitors, entinostat, panobinostat, and
vorinostat to delay tumor growth in xenograft models of RMS
(95, 96). Several HDAC inhibitors are already approved for
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FIGURE 2 | Overview of rhabdomyosarcoma targeted therapies organized by pathway. Therapeutically actionable targets (at least one existing small molecule
inhibitor or antibody) are indicated with an asterisk (*).
treatment of other cancers, but early clinical data show that
HDAC inhibitors against solid tumors are far less effective than
against hematological diseases, likely due to the pharmacokinetic
differences in these two different tumor contexts (97). An
ongoing clinical trial (NCT02780804) of the HDAC1/2/3
inhibitor entinostat in pediatric patients with advanced solid
tumors is expected to shed new insight on HDAC inhibitors in
RMS. Beyond disrupting transcriptional complexes to suppress
the expression of key oncogenic genes, perturbation with HDAC
inhibitors has also been shown to induce transcriptional chaos
in cancer cells, driving cells into terminal differentiation or
apoptotic cell death (98).
Taken together, these studies illustrate that FP RMS cells
are differentially sensitive to the targeted disruption of super-
enhancer complexes. Importantly, the knowledge that FP RMS
cells are selectively dependent on epigenetic readers, writers,
and erasers of the histone acetylation-axis can be exploited in
the pharmacological disruption of these complexes (90). One
important limitation to this approach is that epigenetic regulators
also play a role in normal cellular transcriptional programs,
meaning that there is a narrow therapeutic window and an
increased risk of dose toxicity compared to an approach which
directly targets the chimeric transcription factor.
Modulators of PAX-FOXO1 Activity and Stability
A third approach is to target regulatory post-translational
networks regulating the activity and stability of PAX-
FOXO1. Many of these post-translational modification sites
(phosphorylation, acetylation, methylation) in the fusion protein
have been identified through high throughput mass spectrometry
experiments or in vitro enzymatic screens performed in wildtype
FOXO1 TF (99). However, only some of these sites have been
functionally validated. Of these, most are phosphorylation sites
which are targeted by common kinases, and many of these
kinase are druggable by known kinase inhibitors. In general,
there are two approaches for targeting the regulatory networks of
PAX-FOXO1; (1) targeting the regulatory kinases that influence
protein stability, and (2) targeting the regulatory kinases required
for activation of the fusion protein.
Several phosphorylation sites are known to influence protein
stability of the fusion product. In one study, a two-armed
screening approach of kinome siRNA and small molecules
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identified that the kinase PLK1 stabilizes the fusion protein
by phosphorylating S503. Inhibition of PLK1 directly led
to ubiquitination of the fusion protein, followed by rapid
proteasomal degradation (100). This evidence is consistent with
the known function of PLK1 in the cell cycle, which is to
coordinate entry into mitosis at the G2/M checkpoint. The
expression levels of PAX3-FOXO1 and PLK1 both peak in
G2 in a cell-cycle dependent manner. Upregulation of PAX3-
FOXO1 transcripts and its stabilization by PLK1 phosphorylation
permit the cell to progress past the G2/M checkpoint (101).
Another upstream enzyme, acetyltransferase KAT2B (P/CAF)
is known to modulate fusion protein stability by acetylating
residues K426 and K429 (102). Other phosphorylation sites are
known to control the transcriptional activity of PAX3-FOXO1,
including the residues S201 (phosphorylated by the kinase
GSK3β) (103), S205/S209 (by CK2) (104), and S430 (by CDK4)
(105). Notably, several GSK3β inhibitors significantly suppressed
transcriptional activity of PAX3-FOXO1, leading to inhibition
of cellular proliferation and induction of apoptosis in ARMS
cell lines (106). Given the availability of kinase inhibitors that
have been studied in other human cancers, further functional
validation of post-translational modifications of PAX3-FOXO1




Receptor tyrosine kinases are a family of membrane-bound
cell surface receptors which are aberrantly activated in many
human malignancies. Constitutive activation of RTK signaling
can reprogram numerous intracellular signaling pathways
(metabolism, differentiation, apoptosis, growth) to promote
tumor progression (Figure 2). In FP RMS, overexpressed PAX-
FOXO1 targets include RTKs e.g., FGFR4, CXCR4, IGFR1,
MET, and PDGFRA. In FN RMS, activating mutations in
RTKs caused by molecular lesions can lead to hyperactive
RTK signaling. Taken together, both FP and FN RMS could
benefit from targeting RTK signaling. Generally speaking, the
two strategies for targeting RTKs include small molecule kinase
inhibitors and immunotherapy (monoclonal antibodies, CAR T).
Several studies have shown the that RTK inhibitors can induce
tumor regression in preclinical models (summarized in Table 1).
Despite that many of these candidate targets are currently being
evaluated in early phase I/II trials which recruit RMS patients,
there has only been one clinical trial opened specifically for
RMS patients. This trial (NCT03041701) is open to patients
with relapsed or refractory RMS and its aim is to study the
combination of the IFG-1R monoclonal antibody, ganitumab in
combination with the SRC family kinase inhibitor, dasatinib. This
treatment combination was based on preclinical evidence which
reported that IGF-1R inhibition promotes a bypass resistance
pathway through other kinases, such as the SRC family kinase
YES (107) and ALK (108), suggesting that targeting multiple
RTKs in combination is likely necessary to overcome resistance.
Despite the remarkable genetic and molecular differences
between FP and FN RMS, the RTK/RAS/PI3K axis is commonly
hijacked by both, suggesting that targeting this axis presents
a more general therapeutic approach which could benefit a
wide range of patients. A comprehensive genomic analysis of
147 RMS tumor samples by Shern et al. reported that the
RTK/RAS/phosphoinositide 3-kinase (PI3K) pathway is altered
in 93% of the tumors profiled, mostly dependent on the FGF
and IGF receptor pathways (19). Fortunately, many of these
pathway components (Table 1) can be targeted by clinically
available therapeutics (19). The receptor tyrosine kinase, FGFR4
is frequently mutated and/or overactivated in RMS tumors,
and recent work has implicated the role of FGF signaling in
the evasion of apoptosis (109). Khan et al. identified potaninib
from a panel of five tyrosine kinase inhibitors as a potent
FGFR4 inhibitor that inhibits tumor growth in a RMS mouse
model (110). The receptor tyrosine kinase, IGF2 is another
potential target, given that either loss of imprinting or PAX-
FOXO1-driven gene expression can induce the overexpression
of IGF2 in rhabdomyosarcoma tumors (111). However, a recent
clinical trial evaluating a monoclonal antibody against IGF-1R,
R1507 in advanced sarcoma patients failed to achieve meaningful
clinical responses to the therapy (79). Future studies should
focus on elucidating potential resistance mechanisms to IGF-
1R inhibition and identifying predictive biomarkers for IGF-1R
inhibition sensitivity. A recent publication investigating a MEK
inhibitor, trametinib in combination with IGF-1R inhibition
showed a potent decrease in RMS cell viability and slowed tumor
growth in xenograft models (112). Finally, a randomized phase
II trial of bevacizumab (VEGF-A inhibitor) or temsirolimus
(mTOR inhibitor) in combination with chemotherapy reported
that the relapsed RMS patients who received temsirolimus
achieved a better response (39). Although the RTK/RAS/PI3K
axis is a common platform for therapeutic intervention in both
FP and FN RMS, there is still a need to identify predictive
biomarkers of response. Due to the extensive cross-talk across
RTK signaling axes, combination therapies are likely needed to
derive therapeutic benefit from this approach.Most of the data on
targeting the RTK/RAS/PI3K axis in RMS comes from scattered
preclinical reports, and none have demonstrated significant
single agent activity in early phase clinical trials.
Developmental Pathways
The knowledge that key developmental pathways, such as
Hedgehog and Notch are commonly hijacked in a subset of
RMS tumors can be exploited for therapeutic intervention. The
Hedgehog (Hh) pathway is a highly conserved developmental
pathway, which plays crucial roles in embryonic development,
stem cell biology, and tissue homeostasis (113). In the canonical
Hh pathway, repressive binding of Smoothened (Smo) to
the transmembrane receptor Patched1 (PTCH1) maintains Hh
signaling in an inactive state. Hh ligand binding to PTCH1
releases Smo, which becomes free to activate the Gli family of
transcription factors (114). The link between Hh signaling and
RMS was first described by Hahn et al. in a study of a Patched
knockout mouse model that showed an ERMS phenotype.
The relationship between Hh signaling dysregulation and RMS
has subsequently been supported by several studies (115–118).
Aberrant Hh signaling can be attributed to various germline
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mutations— loss of chromosomal region 9q22 containing PTCH
in 33% of ERMS tumors (119, 120), loss of SUFU in 18%
ERMS tumors (121), and/or genomic amplification of 12q13-15
containing the GLI1 gene in a small subset of ARMS tumors
(116). Several studies have demonstrated that targeting the Hh
pathway can inhibit tumor growth and impair tumor initiation
in xenografted RMS models (118, 122–124). So far, preclinical
evaluation of Smo inhibitors has been difficult to interpret due
to the heterogeneity of response in preclinical models, depending
on the RMS cell line and Smo inhibitor assessed (125, 126).
Recent FDA approval of the Smo inhibitors, vismodegib, and
sonidegib for the treatment of advanced basal cell carcinoma
(BCC) and entry of other Smo inhibitors into clinical trials
for pediatric medulloblastoma raise the possibility of expanding
these inhibitors into clinical trials for pediatric RMS (127).
However, because only a subset of RMS tumors appear to
be sensitive to Smo inhibitors (such as ERMS tumors with a
germline PTCH mutation), more robust predictive biomarkers
for this therapy need to be established (126). Concerns over
the side effects of Smo inhibitors, such as premature closure of
bone growth plates may limit their use to only skeletally mature
patients (128).
The Notch pathway regulates cell fate determination and stem
cell differentiation during tissue development and maintenance.
A recent publication used a zebrafish transgenic model of
ERMS to identify intracellular NOTCH1 (ICN1) as an important
regulator of balancing self-renewal and differentiation in ERMS
(129). This work highlights the mechanistic underpinnings
of the NOTCH1/SNAI1 pathway in driving self-renewal and
blocking MEF2C regulated myogenic differentiation in RMS,
describing a rationale for targeting the NOTCH1/SNAI1/MEF2C
axis in ERMS. Another study highlighted that downregulation
of Notch3 is sufficient to induce RMS cells into a terminal
myogenic differentiation program, suggesting Notch3 as another
potential therapeutic target (130). One group reported that
the oncogenic signaling circuit between the Notch and
YAP pathways drives stemness and tumorigenesis in ERMS,
suggesting a rationale for co-targeting Notch and YAP (131).
Given that there are clinically available gamma-secretase/Notch
signaling pathway inhibitors (RO4929097), Notch1 inhibitors
(MK0752), and Notch1 monoclonal antibodies (brontictuzumab,
tarextumab), these drugs should be expanded into clinical trials
for pediatric RMS.
Cell Cycle Regulators
In order to sustain chronic proliferation, cancer cells must meet
the demanding needs imposed by energy metabolism and cellular
division. The family of cyclin dependent kinases (CDK) which
tightly control the cell cycle are frequently overactive in cancer
cells, and have been extensively investigated as a molecular
vulnerability in various human cancers. Several selective CDK4/6
inhibitors have already been approved for treatment in advanced
stage breast cancer (132), and have been investigated in the
context of RMS, as CDK4 is overexpressed in a subset of
FP RMS tumors through the amplification of chromosomal
region 12q13-q14 (133). CDK4 and its binding partner Cyclin
D are required for progression through the G1/S checkpoint,
and its overexpression allows cancer cells to adapt to the high
proliferation rates needed to sustain tumorigenesis. One study
showed that treatment of rhabdomyosarcoma cell lines and
xenograft models with the clinically available CDK4/6 inhibitor,
palbociclib is sufficient to inhibit proliferation by inducing cell
cycle arrest at G1.
DNA Damage Response (DDR) Pathway
The DNA damage response (DDR) pathway plays a critical role
in normal cellular homeostasis and its dysregulation is closely
linked to increased mutation rates which drive oncogenesis.
The poly(ADP-ribose) polymerases (PARP) belong to a family
of DNA damage sensors which target the poly(ADP-ribose)
polymerase by binding to single strand DNA breaks, recruiting
other components of the homologous recombination (HR)
repair machinery (134). PARP inhibitors (PARPi) are a well-
established class of compounds capable of abrogating single
strand break repair, which are converted into double strand
breaks, subsequently leading deficient DNA repair and cell death
(135). The understanding that inhibition of the DDR can be
exploited in cancer cells to sensitize them to DNA lesions
induced by chemotherapy or RT has been well-established in
other cancers. However, the role of PARP inhibitors in RMS
has not been extensively studied. A recent study showed that
PARP inhibitors can sensitize RMS cell lines to ionizing radiation
(IR), resulting in more potent cytotoxic effects compared to
either modality alone (136). A related study reported that
pretreatment with three PARP1 inhibitors (olaparib, iniparib,
veliparib) was able to sensitize soft tissue sarcoma cells to
radiation by inducing cell cycle arrest at the G2/M checkpoint
(137). Taken together, these data point to the effective approach
of combining PARP inhibitors with radiotherapy, sensitizing
cancer cells to the ionizing radiation and tolerating lower
doses of radiation. A recent preclinical study reported that the
combination of olaparib and temozolomide (DNA-damaging
agent) is a potent therapy for elimination of tumor cells in
a human xenografted tumor zebrafish model of RMS. Both
ERMS and ARMS were sensitive to combination treatment,
suggesting the broad therapeutic potential of PARP inhibition
in RMS (138). While combination therapy of olaparib and
temozolomide is currently being investigated in phase II trials for
Ewing’s sarcoma, there are no open trials for this combination
treatment in rhabdomyosarcoma. The strong preclinical evidence
for the combination therapy of olaparib and temozolomide (138)
warrants further investigation in clinical studies focused on
pediatric RMS.
The Wee1 kinase arrests the cell cycle at the G2/M checkpoint
for necessary DNA repair before entry into mitosis. Because
cancer cells are more reliant on the G2/M checkpoint for
DNA repair than normal cells due to G1/S DNA repair
deficiencies, Wee1 inhibition can halt progression through the
G2/M checkpoint and selectively induce apoptosis in cancer
cells. One preclinical study reported that Wee1 kinase inhibitor
AZD1775 possessed single-agent activity and synergized with
conventional cytotoxic therapy (139). Wee1 inhibition against
a background of cytotoxic drug-induced DNA damage results
in mitotic catastrophe in tumor cells. A recent study used an
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integrated transcriptomic, epigenomic, and proteomic approach
based on orthotopic patient-derived xenografts to validate and
prioritize specific molecular vulnerabilities for high-risk RMS.
The authors identified Wee1 kinase to be the most significant
target for high-risk RMS, which led them to propose that
patients with high-risk and recurrent RMS may benefit from
combination therapy that includes AZD1775, irinotecan, and
vincristine (140). Based on comprehensive preclinical testing
data, patients with high-risk pediatric RMS were included
in a phase I/II clinical trial (NCT02095132) of AZD1775 in
combination with the chemotherapy agent irinotecan. A recent
consensus article by American and European RMS leaders
argued for the prioritization of the WEE1 inhibitor AZD1775 in
combination with vincristine/irinotecan for the next clinical trial
for patients with initially metastatic or recurrent RMS (141).
Apoptosis Pathway
Direct modulation of apoptotic machinery has been exploited
therapeutically in many human cancers, as most cancer cells
are more sensitive to apoptotic induction than normal cells
(142, 143). Because the Bcl-2 family of antiapoptotic proteins
is required for cancer cell survival, inhibiting its function is
one potential therapeutic approach. The development of BH3
mimetics, small molecule inhibitors which mimic the function
BH3-only proteins by antagonizing the pro-survival function
of anti-apoptotic Bcl-2 family, has recently gained traction as
a therapeutic intervention in a number of human cancers.
The Bcl-2 inhibitor, venetoclax is currently under evaluation
in a trial for pediatric neuroblastoma and hematological
malignancies (NCT03236857). Preuss et al. showed that ABT-
737 (BH3 mimetic) and AZD8055 (mTOR inhibitor) cooperate
synergistically to induce the mitochondrial apoptotic pathway
in ERMS and ARMS cell lines (144). Another study showed
that venetolax sensitized RMS cells to JNJ, an HDAC inhibitor
(145). Taken together, these findings suggest that BH3 mimetics
synergize with other targeted therapies by priming cancer cells to
be sensitive to apoptotic induction.
A related strategy is the inhibition of X-linked Inhibitor of
Apoptosis Proteins (XIAP), a family of proteins which block
apoptosis by directly binding and inhibiting caspases, and which
are frequently overexpressed in cancer cells. Smac mimetics
are a class of molecules designed to mimic the endogenous
antagonist of XIAPs, second mitochondrial activator of caspases
(Smac). Upon activation of themitochondrial apoptotic pathway,
Smac is released into the cytosol, where it binds and neutralizes
XIAPs, thereby allowing the caspase cascade to proceed. One
study reported that Smac mimetics sensitized two RMS cell lines
toward natural killer (NK) cell-mediated killing in an apoptotic-
dependent manner (146). Currently, several Smac mimetics are
being evaluated in early clinical trials for other human cancers
but there are no open trials for RMS (147).
IMMUNOTHERAPY
Targeting PAX-FOXO1 as a Tumor Antigen
The recurrent 2;13 and 1;13 translocations in FP RMS encode
for the PAX3-FOXO1 and PAX7-FOXO1 chimeric transcription
factors, which are uniquely expressed in malignant cells but
not in normal cells. This raises the possibility that the PAX-
FOXO1 chimeric proteins can be leveraged as novel tumor-
associated antigens in immunotherapy. The unique translocation
breakpoint region may be processed, displayed on the tumor
cell surface by major histocompatibility complex Class I (MHC-
I) molecules, and targeted for killing by cytotoxic T cell
lymphocytes (CTL) (148, 149). While data from preclinical
mouse studies highlighted the vaccine-based approach as a
promising strategy (149), a pilot clinical trial that generated
vaccines by pulsing immature dendritic cells from breakpoint
region peptides failed to improve patient outcomes (150). A
separate study generated a human CTL line capable of lysing
HLA-B7 rhabdomyosarcoma tumor cells (151). However, due
to the limitation that this vaccine would only be applicable
to the minority of the population who express the HLA-B7
allele, its clinical potential is limited. Attempts to generate
vaccines targeted against other class I molecules including
HLA-A1, HLA-A2, HLA-A3 are unlikely to be successful,
as predicted by MHC-peptide binding algorithims (152). A
pilot trial of consolidative immunotherapy (integration of
immunotherapy into a multi-modal chemotherapeutic regimen),
which administered vaccines of dendritic cells pulsed with
breakpoint peptides reported positive outcomes in patients
with high-risk pediatric ARMS, highlighting that vaccine-based
approaches targeting the fusion protein could still be a valuable
strategy. However, there is still room for improvement in
refining this approach, such as using alternative approaches
for generating more potent dendritic cells and identification
of immunogenic peptides (153). New models that predict
the immunogenicity of MHC-binding peptides from tumor
transcriptomes can be leveraged to identify novel immunogenic
peptides (154).
Monoclonal Antibodies
In the last two decades, monoclonal antibodies (mAbs)
have become standard-of-care treatment of several human
malignancies, but its role in RMS is not well established.
Monocolonal antibodies can directly target cancer cells
through a number of mechanisms, including inhibition of
oncogenic signaling pathways, delivery of cytotoxic moieties to
malignant cells, or induction of antibody-dependent cellular
toxicity (155). One strategy has been the development of an
Fc-enhanced anti-B7-H3 monoclonal antibody to target the
B7-H3 protein upregulated on the surfaces of many pediatric
solid tumor cells (156). Based on support from preclinical
testing, a Phase I study was opened to evaluate enoblituzumab,
an Fc-enhanced, humanized IgG1 monoclonal antibody
specific for B7-H3 and engineered with an Fc domain with
increased affinity for the activating receptor CD16A, thereby
enhancing antibody dependent cellular cytotoxicity (ADCC)
(157). Compared to classical mAb therapies which are less
effective due to the existence of natural polymorphisms of
FcγR, the strategy of fine tuning the Fc domain to optimize
effector cell function should be considered in mAb-based
approaches for RMS.
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CAR T-Cells
Early phase clinical studies of CAR T cell therapy for patients
with pediatric solid tumors has demonstrated that while it can be
safely administered, antitumor activity is limited (158). Targeting
the human epidermal growth factor receptor 2 (HER2) expressed
on tumor cells with the anti-HER2 antibody trastuzumab is an
established therapy for the treatment of HER2-positive breast
cancers (159, 160). Given that a subset of sarcomas express HER2
on tumor cell surfaces, targeting this receptor by immunotherapy
is one potential strategy. Because HER2 expression levels are too
low in sarcoma cells for a monoclonal antibody-based approach
to be therapeutically actionable, HER2-positive sarcoma patients
may be more sensitive to HER2-directed CAR T cell therapy
(161). Following preclinical evaluation of a HER2-specific CAR
containing a CD28.ζ signaling domain, Navai et al. (162)
conducted a small phase I study (NCT00902044) evaluating the
efficacy of HER2-targeted CAR T-cell therapy in combination
with lymphodepletion chemotherapy in patients with advanced
HER2-positive sarcoma. One pediatric RMS patient treated
achieved a complete response for 12 months, but relapsed later
(163). Another recent preclinical study of CAR T cells targeting
B7-H3 (an immune checkpoint antigen) in xenograft models of
various pediatric solid tumors, including RMS demonstrated that
they could induce tumor regression in xenograft models (164).
Other potential cell surface immune targets (FGFR4, SLC19A1,
ACVR2A, EPHB4) were identified by Khan et al., in a study
which used gene expression datasets to rank potential immune
targets by their differential expression between 12 pediatric
cancer tissues and normal tissue (165). Such gene expression
approaches can be a useful strategy to generate a list of possible
immune targets, but validation that these targets are actually
expressed at the protein level on tumor cells (and not expressed
on normal cells) is required before they are considered for
CAR T therapy.
Compared to the success of CAR T cell therapy for treating
B-cell-derived malignancies, the clinical efficacy of CAR T cell
therapy to pediatric solid tumors has so far been limited. As
reviewed by DeRenzo et al., treatment of solid pediatric tumors
presents a unique set of challenges that must be carefully taken
into consideration. Challenges of designing CAR T cell therapy
for solid tumor malignancies include: heterogeneous antigen
expression, limited migration of T cells to tumor sites, and an
immunosuppressive, hostile microenvironment (158). In order
to advance the field of CAR T cell therapy in pediatric solid
tumors, there is a need for further optimization of CAR T cells at
the preclinical stage, identification of immunogenic targets, and
a technique to non-invasively monitor CAR T activity in patients
in the clinical trial stage (158).
Immune Checkpoint Blockade
Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and
programmed cell death protein 1 (PD-1) belong to a class of
inhibitory receptors, which are negative regulators of T-cell
immune function. In a tumor context, cancer cells have evolved
mechanisms to co-opt this system, enabling cancer cells to evade
immune surveillance. For example, when PD-1 receptor on T
cells is engaged by its native ligand, PD-L1, T cell effector
function is inhibited. Thus, tumor cells have evolved to express
PD-L1 on their surfaces to deactivate T cell effector function,
enabling them to evade destruction by the immune system.
Release of the negative regulators at these checkpoints with
checkpoint blockade therapy can induce a latent anti-tumor
immune response (166). Given the clinical success of immune
checkpoint inhibitors in metastatic melanoma and metastatic
squamous non-small cell lung cancer, early-phase clinical trials
are currently investigating their clinical efficacy in pediatric solid
tumors (167–169).
Ipilimumab is a first-in-class anti-CTLA-4 immune
checkpoint inhibitor approved for treatment of metastatic
melanoma and was recently evaluated in a phase I clinical trial
for the treatment of pediatric advanced solid tumors. Even
though ipilimumab is safely tolerated in these patients, its
efficacy as a monotherapy is limited. The authors of this study
recommend future investigation of anti-CTLA-4 therapy in
combination with other checkpoint inhibitors and/or immune-
modifying agents (170). Targeting the PD-1/PD-L1 axis by mAb
therapy (nivolumab, pembrolizumab) has a similar mechanism
to CTLA-4 therapy, in which brakes are released on the anti-
tumor activity of T cells. A pilot phase I trial (NCT01445379) of
ipilimumab in children with advanced refractory solid tumors
showed that no objective tumor regressions were achieved (170).
Combination therapy of both CTLA-4 and PD-L1 inhibitors have
demonstrated clinical efficacy in advanced melanoma, suggesting
its consideration in pediatric cancers (171, 172). Initial data
from an ongoing phase I/II trial (NCT02304458) evaluating
nivolumab with/without ipilimumab in children with recurrent
or refractory solid tumors or sarcomas showed that single-agent
nivolumab has no activity, but in combination with ipilimumab
demonstrated efficacy in certain sarcoma subtypes (173).
It is unlikely that immune checkpoint blockade in pediatric
patients will achieve the same levels of response seen in adult
patients. In adult cancers, a high mutational burden (more
neoantigens) is correlated with a strong response to immune
checkpoint inhibitors. Pediatric cancers are characterized by a
lowmutational burden, but it may be interesting to study whether
RMS patients with higher mutational burdens (ERMS subtype)
are more responsive to immune checkpoint therapy. Moreover,
children do not yet have a fully developed immune system, which
is required for optimal response to immunotherapy. Finally,
the highly immunosuppressive microenvironment of pediatric
sarcomas due to the presence of regulatory T cells and myeloid-
derived suppressor cells limits the efficacy of immunotherapy.
FUTURE DIRECTIONS—PERSONALIZED
THERAPY AND OVERCOMING DRUG
RESISTANCE
In an ideal world with unlimited financial resources and time,
drug development efforts would be focused on developing
pediatric cancer-specific drugs, such as a direct inhibitor of the
PAX-FOXO1 fusion protein uniquely expressed in FP RMS. In
reality, few drugs have been developed specifically for childhood
cancers due to a small market for a rare childhood diseases, and
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the ability to directly target PAX-FOXO1 does not appear to be
within reach for some time. For now, most clinical trials opened
for RMS exploit known drugs targeting common pathways which
are dysregulated in other human cancers (Figure 2). Careful
review of how targeted therapies have been successful in clinical
trials for other human malignancies [e.g., immune checkpoint
blockade in metastatic melanoma (168, 169, 172, 174, 175)]
and systematic analysis of clinical trials of related families of
childhood cancers [e.g., PARP inhibition in Ewing’s sarcoma
(138)] provide valuable insight into translating these therapies
into a RMS tumor context.
In FP RMS, one strategy to target PAX-FOXO1 has been
the selective disruption co-regulatory and post-translational
networks of PAX-FOXO1 with clinically approved inhibitors.
While such approaches have shown encouraging responses
in preclinical studies, these targets have normal physiological
functions unrelated to the fusion protein, so careful consideration
must be given to off-target effects. On the other hand, FN RMS
(lacking the chimeric transcription factor) harbors recurrent
genetic alterations (RAS, FGFR4, IGFR1, CDK4, PI3KCA, etc.),
conferring these tumors molecular dependencies which can be
targeted by clinically available drugs (19).
Based on data from early clinical trials enrolling pediatric
rhabdomyosarcoma patients, single-agent therapies do not
appear to achieve durable responses. As with most targeted
therapies, almost all cancers treated with a single-agent therapy
will eventually acquire resistance and reduced sensitivity to
subsequent lines of treatment. Of equal importance to identifying
novel therapeutic targets, is the unequivocal need to better
understand how RMS tumors develop resistance to these
therapies. Given the recent surge of research completed to
characterize the genomic, epigenomic, transcriptomic, and
proteomic landscape of rhabdomyosarcoma (117, 140), we
now have a comprehensive list of therapeutic vulnerabilities,
which are currently under preclinical and clinical evaluation.
However, narrowly focusing on identifying these targets is
inadequate, and a commensurate amount of effort ought to be
given to studying mechanisms of resistance to targeted therapy.
For patients diagnosed with metastatic rhabdomyosarcoma,
insufficient local therapy options and incomplete eradication of
occult microscopic residual disease are the most common causes
of treatment failure (176). These new targeted therapies and
immunotherapies hold promise for patients with metastatic or
recurrent RMS, but only insofar as we concurrently advance our
understanding of how to overcome inevitable drug resistance.
While the identification of novel therapeutic vulnerabilities for
RMS is gaining significant traction, it is equally important for
clinicians to remain one step ahead by being able to anticipate
resistance mechanisms and to identify strategies to overcome
resistance accordingly.
Even the most successful targeted therapies that have
been approved for the treatment of human cancers fail to
completely eliminate residual disease in patients, leading to
eventual relapse despite an initial response. A bulk solid tumor,
such as rhabdomyosarcoma is composed of a heterogeneous
population of cells which evolves to be more genetically unstable
and complex as selective pressure is applied during drug
treatment (177). Pediatric cancers are characterized by dynamic
chromosomal instability, which can result in loss of chromosomal
segments or copy-number alterations, contributing to the
genetic heterogeneity of the tumor mass. A small subpopulation
of drug-resistant tumor cells (harboring a genetic alteration
conferring a survival advantage) present at initial treatment may
persist and expand, resulting in eventual failure to eliminate
residual tumor mass. Generally speaking, the two known
strategies for overcoming drug resistance are intermittent dosing
schedules and combination therapies. Intermittent dosing relies
on the principle that periods of interspersed drug-withdrawal
between drug-treatments can restore drug sensitivity by allowing
drug-sensitive subpopulations to repopulate the tumor mass.
Mathematical modeling can be used to predict the optimal dosing
schedules which can sustain drug sensitivity, as demonstrated
by a study which used an algorithm to design a tyrosine kinase
inhibitor (TKI) dosing schedule for treatment of non-small
cell lung cancers (178). These modeling platforms should be
integrated into the design of future clinical trials for TKIs in RMS,
where TKIs such as IGF-1R have demonstrated limited efficacy
so far in early phase clinical trials (79, 179). A second approach
is to anticipate which pre-existing subclonal populations will be
drug-resistant, identify molecular vulnerabilities for these drug-
resistant subclones, and design combination therapies focused on
eradicating the maximal percentage of the heterogeneous tumor
mass during first-line therapy. As an example, one study in non-
small lung cell cancers showed that drug-resistant tumor cells
with acquired resistance conferred by the EGFRT790M mutation
could be re-sensitized to EGFR TKIs by co-targeting them with
navitoclax, an inhibitor of BCL-2 and BCL-XL (180). With the
expansion of CRISPR-Cas9-based gene editing systems, we now
have the ability to conduct unbiased genome-wide screens for
therapeutic vulnerabilities in RMS to identify synthetic lethal
combinations (181, 182).
Initial efforts to bring immunotherapies designed for
adults into rhabdomyosarcoma pediatric trials has been
met with limited success. These immunotherapies fail to
translate because pediatric solid tumors are characterized by
a lower mutational burden and a non-inflammatory tumor
microenvironment (defined by very few infiltrating T cells
and low levels of chemokines/cytokines) (183). Although
further study is needed to elucidate the landscape of the
RMS tumor microenvironment, pediatric solid tumors are
generally regarded as less “inflamed” than adult tumors (184).
As recently reviewed here (183), patients with “hot” tumor
microenvironments (immune infiltrated) respond better to
immune checkpoint blockade, whereas patients with “cold”
tumor microenvironments (immune non-infiltrated) are better
suited for adoptive T cell therapy. Further characterization of
the tumor microenvironment of rhabdomyosarcoma would help
guide the choice of an immunotherapeutic approach.
As whole-genome and transcriptome sequencing of
rhabdomyosarcoma tumors has revealed, the genomic diversity
of this disease requires a personalized (genotype-guided)
approach to therapy. The presence or absence of the PAX-
FOXO1 fusion gene reflects the vast genetic and molecular
differences between FP and FN tumors, and this prognostic
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marker should guide the design of therapies specific to each
subclass (37). Multi-region sampling of the tumor, single-cell
sequencing, autopsy analysis, and longitudinal analysis of liquid
biopsy samples can be used to reconstruct a holistic picture of
tumor evolution in response to drug treatment, which can guide
clinical decisions to counteract potential drug resistance (177).
The gap between the observed efficacy of targeted therapies
in preclinical models of RMS and the marginal improvements
in patient outcomes observed in clinical trials has forced a
reconsideration of our approach. Only when the mechanisms
of drug resistance are understood will these new treatments
be effective for children with metastatic or recurrent RMS,
for which intensive chemotherapeutic regimens have already
been exhausted.
CONCLUSION
Our current understanding of the genomic and molecular
landscape of rhabdomyosarcoma has equipped us with a
valuable list of potential targets for targeted therapy and
immunotherapy based approaches. Effective clinical translation
of these agents remains an ongoing challenge, underscoring
the need to elucidate why tumors eventually acquire resistance
to targeted therapy. Given the small number of patients
available for enrollment in clinical trials, it is necessary to
prioritize which therapeutic targets and combination therapies
will have the most clinical benefit for the greatest number
of patients. The marked heterogeneity across RMS subtypes
(and specifically within the ERMS subtype) means more
personalized, genotype-guided approaches are needed to inform
treatment decisions. As such, there is a need to identify
reliable and objective biomarkers to determine the most
effective therapy for each patient. With the inadequate outcomes
observed in early RMS clinical trials of targeted therapies and
immunotherapy, the conversation must shift toward how we
can close the gap between the preclinical and clinical efficacy of
these therapies.
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